Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.44 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | SCN4A | P35499 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL475215 | 0.88 | SMN1; SMN2 (0.48) | LMNALTA4HSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL8925998 | 0.88 | SMN1; SMN2 (0.48) | LMNALTA4HSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL13925528 | 0.85 | — | — | |
| SCHEMBL131869 | 0.85 | — | — | |
| Ammonia Solution, Strong SCHEMBL143304 | 0.83 | LMNA (0.70) | LMNAL3MBTL1ALDH1A1GAARAB9A | |
| SCHEMBL12013124 | 0.83 | LTA4H (0.51) | LMNALTA4HEPHX2MAOBALDH1A1 | |
| SCHEMBL17450471 | 0.82 | FFAR4 (0.43) | LMNAL3MBTL1LTA4HEPHX2SOS1 | |
| SCHEMBL16933880 | 0.81 | S1PR1 (0.46) | LMNALTA4HMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL20848358 | 0.81 | MAOB (0.67) | LMNAMAOBAPPNPC1RAB9A | |
| SCHEMBL8429859 | 0.81 | FDFT1 (0.46) | LTA4HEPHX2MAOBSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020133123-A1 | OXIME-TETRAZOLE DERIVATIVE AND APPLICATION THEREOF IN AGRICULTURE | 东莞市东阳光农药研发有限公司 | 2020-07-02 | — | — | WO | disclosed |
| EP-3125884-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018144900-A1 | SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2018-08-09 | — | — | WO | disclosed |
| US-9394303-B2 | Small molecule inhibitors of MCL-1 and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-07-19 | — | — | US | disclosed |
| US-9309260-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| WO-2015153959-A2 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150284387-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-08 | — | — | US | disclosed |
| US-9085587-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2011-05-19 | — | — | US | disclosed |
| US-20100286364-A1 | GLYCOSYLATED GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286364-A1 | GLYCOSYLATED GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | disclosed |
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
| US-20090143386-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2009-06-04 | — | — | US | disclosed |
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284387-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | MCL1, BCL2L1, API5 | LMNA 2260/4885L3MBTL1 189/4885LTA4H 3825/4885 |
| US-20100286364-A1 | GLYCOSYLATED GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES | CSGALNACT1, OGT, GALNT1 | LMNA 3861/4885L3MBTL1 1717/4885LTA4H 3885/4885 |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | ADAM10, ADAM12, ADAM17 | LMNA 1700/4885L3MBTL1 1241/4885LTA4H 1842/4885 |
| US-20090143386-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, CASP10 | LMNA 3464/4885L3MBTL1 2551/4885LTA4H 2318/4885 |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A2, GUCY1A1 | LMNA 532/4885L3MBTL1 1253/4885LTA4H 1075/4885 |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A2, GUCY1A1 | LMNA 532/4885L3MBTL1 1253/4885LTA4H 1075/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | LMNA 320/4885L3MBTL1 1217/4885LTA4H 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.